The estimated Net Worth of Lindsay A Md Rosenwald is at least $1.31 million dollars as of 11 July 2024. Lindsay Rosenwald owns over 5,000 units of Fortress Biotech Inc stock worth over $224,400 and over the last 18 years he sold FBIO stock worth over $0. In addition, he makes $1,090,020 as Executive Chairman of the Board, President et Chief Executive Officer at Fortress Biotech Inc.
Sign up
Lindsay Rosenwald FBIO stock SEC Form 4 insiders trading
Lindsay has made over 34 trades of the Fortress Biotech Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of FBIO stock worth $37,400 on 11 July 2024.
The largest trade he's ever made was buying 2,395,209 units of Fortress Biotech Inc stock on 10 February 2023 worth over $2,011,976. On average, Lindsay trades about 84,626 units every 54 days since 2006. As of 11 July 2024 he still owns at least 127,500 units of Fortress Biotech Inc stock.
You can see the complete history of Lindsay Rosenwald stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lindsay Rosenwald biography
Dr. Lindsay A. Rosenwald M.D. serves as Executive Chairman of the Board, President, Chief Executive Officer of the Company. Dr. Rosenwald also serves as a director of Mustang Bio, Inc., Chairman of the Board of Directors of Avenue Therapeutics, Inc., and a director of Checkpoint Therapeutics, Inc. From November 2014 to August 2015, he served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc. Dr. Rosenwald is also Co-Portfolio Manager and Partner of Opus Point Partners Management, LLC (“OPPM”), an asset management firm in the life sciences industry, which he joined in 2009. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 25 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine. Based on Dr. Rosenwald’s biotechnology and pharmaceutical industry experience and in-depth understanding of the Company’s business, the Board of Directors believes that Dr. Rosenwald has the appropriate set of skills to serve as a member of the Board in light of the Company’s business and structure.
What is the salary of Lindsay Rosenwald?
As the Executive Chairman of the Board, President et Chief Executive Officer of Fortress Biotech Inc, the total compensation of Lindsay Rosenwald at Fortress Biotech Inc is $1,090,020. There are 1 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
How old is Lindsay Rosenwald?
Lindsay Rosenwald is 65, he's been the Executive Chairman of the Board, President et Chief Executive Officer of Fortress Biotech Inc since 2013. There are 5 older and 6 younger executives at Fortress Biotech Inc. The oldest executive at Fortress Biotech Inc is Malcolm Hoenlein, 76, who is the Independent Director.
What's Lindsay Rosenwald's mailing address?
Lindsay's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Insiders trading at Fortress Biotech Inc
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss et George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
What does Fortress Biotech Inc do?
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
What does Fortress Biotech Inc's logo look like?
Complete history of Lindsay Rosenwald stock trades at Fortress Biotech Inc, Alaunos Therapeutics Inc, Checkpoint Therapeutics Inc, Avenue Therapeutics Inc, Mustang Bio Inc et Fortress Biotech Inc
Fortress Biotech Inc executives and stock owners
Fortress Biotech Inc executives and other stock owners filed with the SEC include:
-
Robyn Hunter,
Chief Financial Officer, Treasurer, Secretary -
Michael Weiss,
Executive Vice Chairman - Strategic Development, Director -
Lindsay Rosenwald,
Executive Chairman of the Board, President, Chief Executive Officer -
Robyn M. Hunter,
CFO, Treasurer & Corp. Sec. -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman, Pres & CEO -
Michael S. Weiss Esq.,
Vice Chairman & Exec. Vice Chairman of Strategic Devel. -
George Avgerinos,
Senior Vice President - Biologics Operations -
Eric Rowinsky,
Co-Vice Chairman and Director -
J. Jay Lobell,
Independent Director -
Dov Klein,
Independent Director -
Jimmie Harvey,
Independent Director -
Malcolm Hoenlein,
Independent Director -
Kevin Lorenz,
Independent Director -
Jaclyn Jaffe,
IR Contact Officer -
Dr. Thomas F. Schaible,
Project Leader of Inflammatory Bowel Disease -
David Jin,
Chief Financial Officer -
Lucy Lu,
Director